Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, Pirklbauer M, Graziadei I, Gänzer H, von Bary C, May AE, Wöll E, von Scheidt W, Rassaf T, Duerschmied D, Brenner C, Kääb S, Metzler B, Joannidis M, Kain HU, Kaiser N, Schwinger R, Witzenbichler B, Alber H, Straube F, Hartmann N, Achenbach S, von Bergwelt-Baildon M, von Stülpnagel L, Schoenherr S, Forer L, Embacher-Aichhorn S, Mansmann U, Rizas KD, Massberg S, Bantkowiak M, Baur G, Baylacher M, Beaucamp M, Berger M, Besch L, Brunner S, Budweiser S, Bugger H, Coletti R, Dorwarth U, Egresits J, Eiffener E, Faul C, Finkenstedt A, Gatos K, Gauchel N, Gindele F, Grander W, Gunschl M, Hartig F, Hecht M, Heer T, Heger L, Hentrich M, Horvath L, Keta D, Kiechl S, Kirchmaier R, Klein A, Klemm M, Kolesnik E, König A, Kossmann HC, Kropacek J, Lanser L, Lother A, Löw A, Mahabadi AA, Malleier S, Mayer G, Müller C, Müller-Wieland D, Nagel B, Neuwirt H, Olivier C, Raunegger T, Reindl M, Reinstadler S, Riesinger L, Schäffner M, Schier J, Schock J, Schönherr P, Schulz M, Schütz T, Schwarz J, Siebmaier J, Siry M, Spaur A, Sturm W, Tessadri K, Theurl F, Theurl M, Thommes L, Tiller C, Toifl M, Totzeck M, von zur Mühlen H, Vonderlin N, Wakili R, Wendtner C, Wenner F, Wimmert-Roidl D, Zabernigg A (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 9

Pages Range: 863-872

Journal Issue: 8

DOI: 10.1016/S2213-2600(21)00214-9

Abstract

Background: SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme 2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed to test our hypothesis that discontinuation of chronic treatment with ACE-inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) mitigates the course o\f recent-onset COVID-19. Methods: ACEI-COVID was a parallel group, randomised, controlled, open-label trial done at 35 centres in Austria and Germany. Patients aged 18 years and older were enrolled if they presented with recent symptomatic SARS-CoV-2 infection and were chronically treated with ACEIs or ARBs. Patients were randomly assigned 1:1 to discontinuation or continuation of RAS inhibition for 30 days. Primary outcome was the maximum sequential organ failure assessment (SOFA) score within 30 days, where death was scored with the maximum achievable SOFA score. Secondary endpoints were area under the death-adjusted SOFA score (AUCSOFA), mean SOFA score, admission to the intensive care unit, mechanical ventilation, and death. Analyses were done on a modified intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT04353596. Findings: Between April 20, 2020, and Jan 20, 2021, 204 patients (median age 75 years [IQR 66–80], 37% females) were randomly assigned to discontinue (n=104) or continue (n=100) RAS inhibition. Within 30 days, eight (8%) of 104 died in the discontinuation group and 12 (12%) of 100 patients died in the continuation group (p=0·42). There was no significant difference in the primary endpoint between the discontinuation and continuation group (median [IQR] maximum SOFA score 0·00 (0·00–2·00) vs 1·00 (0·00–3·00); p=0·12). Discontinuation was associated with a significantly lower AUCSOFA (0·00 [0·00–9·25] vs 3·50 [0·00–23·50]; p=0·040), mean SOFA score (0·00 [0·00–0·31] vs 0·12 [0·00–0·78]; p=0·040), and 30-day SOFA score (0·00 [10–90th percentile, 0·00–1·20] vs 0·00 [0·00–24·00]; p=0·023). At 30 days, 11 (11%) in the discontinuation group and 23 (23%) in the continuation group had signs of organ dysfunction (SOFA score ≥1) or were dead (p=0·017). There were no significant differences for mechanical ventilation (10 (10%) vs 8 (8%), p=0·87) and admission to intensive care unit (20 [19%] vs 18 [18%], p=0·96) between the discontinuation and continuation group. Interpretation: Discontinuation of RAS-inhibition in COVID-19 had no significant effect on the maximum severity of COVID-19 but may lead to a faster and better recovery. The decision to continue or discontinue should be made on an individual basis, considering the risk profile, the indication for RAS inhibition, and the availability of alternative therapies and outpatient monitoring options. Funding: Austrian Science Fund and German Center for Cardiovascular Research.

Authors with CRIS profile

Involved external institutions

Medizinische Universität Innsbruck Austria (AT) Klinikum der Universität München Germany (DE) Landeskrankenhaus Hall Austria (AT) Bezirkskrankenhaus Schwaz Austria (AT) Technische Universität München (TUM) Germany (DE) Klinikum Memmingen Germany (DE) Hospital St. Vincent Zams Austria (AT) Universitätsklinikum Augsburg Germany (DE) Universitätsklinikum Essen Germany (DE) Albert-Ludwigs-Universität Freiburg Germany (DE) InnKlinikum gKU Altötting und Mühldorf Germany (DE) Bezirkskrankenhaus St. Johann in Tirol Austria (AT) Klinikum Weiden Germany (DE) HELIOS Kliniken Germany (DE) Klinikum Klagenfurt am Wörthersee Austria (AT) München Klinik Bogenhausen Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Ludwig-Maximilians-Universität (LMU) Germany (DE)

How to cite

APA:

Bauer, A., Schreinlechner, M., Sappler, N., Dolejsi, T., Tilg, H., Aulinger, B.A.,... Zabernigg, A. (2021). Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. The Lancet Respiratory Medicine, 9(8), 863-872. https://dx.doi.org/10.1016/S2213-2600(21)00214-9

MLA:

Bauer, Axel, et al. "Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial." The Lancet Respiratory Medicine 9.8 (2021): 863-872.

BibTeX: Download